FDA approves Moderna’s mRNA flu vaccine
Ella Jeffries / beckershospitalreview - The FDA has approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based influenza vaccine in the U.S., for the prevention of seasonal influenza in adults ages 50 and older. The decision follows a monthslong regulatory process that included the agency’s …
AI Summary: The FDA has approved Moderna's mRNA flu vaccine, giving the familiar seasonal bug a high-tech reboot. Regulators cleared Moderna’s mRNA formulation for public use, signaling a shift toward next-generation influenza vaccines; rollout details, target groups and supply plans will follow as public health authorities coordinate distribution for the coming flu season.
Related Stories
U.S. flu vaccine showed unusually low effectiveness this season / 4 months
FDA to review Moderna’s experimental flu vaccine after reversal / 5 months
FDA vaccines chief Vinay Prasad to step down in April / 4 months
Vanderbilt’s experimental C. diff vaccine shows promising protection / 5 months
Nasal-spray ‘universal’ vaccine protects mice from many respiratory threats / 5 months
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 6 months
FDA rejects Corcept’s cortisol modulator triggering setback / 7 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Cancer Research, Infectious Disease, Supply Chain, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine